Drug intelligence / Profile preview

17 beta-estradiol + progesterone

Development stage
Phase 4
Lead developer
TherapeuticsMD
Modality
Small Molecules
Administration
Transdermal, Oral
01

Overview

This hormone replacement therapy (HRT) regimen, evaluated by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), consists of transdermal 17 beta-estradiol and oral micronized progesterone. It is specifically investigated for the treatment of premature ovarian insufficiency (POI) in female adolescents aged 11 to 19 years. The regimen aims to mimic physiological hormone levels to induce puberty or provide maintenance therapy, thereby mitigating long-term risks associated with hypoestrogenism, such as osteoporosis, cardiovascular disease, and psychological distress. The 17 beta-estradiol is administered via a transdermal patch with escalating doses (25 to 100 micrograms), while progesterone is added cyclically (100 mg/day for 12 days/month) to protect the endometrium and induce withdrawal bleeding.

Other names
17 beta-estradiolestradiolprogesteroneHormone Replacement TherapyHRT
02

Targets

ESR1 (ERα)ESR2 (ERβ)PR (Progesterone receptor)

Beyond the preview

Go deeper on 17 beta-estradiol + progesterone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 17 beta-estradiol + progesterone.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call